Sun Pharmaceutical Industries, Inc. has received FDA approval for its Abbreviated New Drug Application for the oral formulation of TRAMADOL HYDROCHLORIDE, positioning the company to expand its generic pain management portfolio and leverage significant market opportunities. This clearance supports the introduction of a cost-effective alternative critical for enhancing patient access to opioid analgesics.